Off-Label Medications for Anxiety Disorders

Introduction to Off-Label Treatments

The Canadian Clinical Practice Guidelines recommend benzodiazepines as second-line agents for rapid anxiety relief when first-line treatments fail, with benzodiazepines and pregabalin having the strongest evidence as second-line agents when SSRIs/SNRIs fail 1

Benzodiazepines are recommended as second-line agents for rapid anxiety relief when first-line treatments fail, but are not recommended for routine first-line use due to dependence potential 1, 2
Common benzodiazepines and typical dosing include:

Pregabalin has demonstrated efficacy as a second-line treatment for anxiety disorders according to Canadian guidelines, with dosing starting at 150 mg/day in 2-3 divided doses and targeting 300-600 mg/day in 2-3 divided doses 1, 2
Gabapentin is recommended as a second-line option, particularly for patients with comorbid pain conditions, with dosing starting at 300 mg once daily or 300 mg three times daily and targeting 900-3600 mg/day in 3 divided doses 1, 2

Clomipramine can be used off-label for anxiety disorders, with dosing starting at 25 mg at bedtime, titrating up to 100-250 mg/day, and having a maximum dose of 250 mg/day 2, 4

When SSRIs/SNRIs fail or are not tolerated, consider adding or switching to pregabalin (300-600 mg/day) or gabapentin (1200-3600 mg/day), especially if comorbid pain exists, and always combine with CBT 1, 2
For rapid relief needed, consider short-term benzodiazepine (clonazepam 0.5-2 mg/day or alprazolam 1-4 mg/day) while titrating other agents 1
For GAD specifically, consider quetiapine 150-300 mg/day if other options fail, weighing metabolic risks 1

Benzodiazepine dependence is a concern, and duration should be limited with the lowest effective dose used; avoid in patients with substance use history 2
Inadequate trial duration can lead to premature switching, as off-label agents may require 8-12 weeks for full effect, similar to SSRIs 4
Polypharmacy without rationale should be avoided, ensuring adequate trials of first-line agents before adding off-label medications 1, 2